Innovations + Investments in Healthcare Summit 2015
Innovations + Investments in Healthcare Summit 2015


AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:

AstraZeneca RSS Channel

Title Filter      Display #  
# Article Title
1 AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours
2 AstraZeneca provides update on brodalumab development programme
3 AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden
4 AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits
5 FDA grants Priority Review for potential new indication for Brilinta
6 AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology
7 AstraZeneca and PatientsLikeMe announce global research collaboration
8 AstraZeneca joins Genomics England consortium
9 AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes
10 AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD
11 PEGASUS-TIMI 54 study shows that long-term treatment with BRILINTA reduced thrombotic cardiovascular events in patients with a history of heart attack
12 AstraZeneca completes acquisition of rights to Actavis’ branded respiratory portfolio in the US and Canada
13 AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada
14 AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform
15 MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
16 Jury verdict favours AstraZeneca in Nexium antitrust litigation
17 Amgen and AstraZeneca announce positive results from third and final pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis
18 AstraZeneca announces initiation of development programme for BRILINTA® reversal agent
19 AstraZeneca launches Healthy Heart Africa programme to address hypertension in Africa
20 AstraZeneca strengthens partnership with the University of Cambridge
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner


Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]